Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Neoplasm Metastasis × eribulin × Clear all

Phase

Phase 2 5 Phase 3 4 Phase 1/2 3 Phase 1 3 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Neurotoxicity Syndromes 1 Neoplasm Metastasis 1 Drug-Related Side Effects and Adverse Reactions 1

Interventions

Zoledronic Acid 3 Bevacizumab 3 exemestane 2 Therapeutics 2 Oxaliplatin 2 Misoprostol 2 Magnetic Resonance Spectroscopy 2 Letrozole 2 Ibandronic Acid 2 Fluorouracil 2 Cetuximab 2 Capecitabine 2 vandetanib 1 palbociclib 1 liposomal doxorubicin 1 huaier 1 eribulin 1 enzalutamide 1 darolutamide 1 cabozantinib 1 aldesleukin 1 Vindesine 1 Trastuzumab 1 Sugars 1 Stents 1 Standard of Care 1 Sorafenib 1 Radiosurgery 1 Platinum 1 Pharmaceutical Preparations 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01961544 2016-10-07

ESKIMO

Eisai Inc.

Phase 4 Completed

101 enrolled 6 charts

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡